Published in Oncogene on October 08, 2007
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting (TAPG) | NCT03912883
Clonal evolution in cancer. Nature (2012) 11.07
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A (2011) 2.46
ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 2.43
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 2.29
Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med Genomics (2011) 2.24
Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res (2013) 2.10
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 1.77
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest (2010) 1.48
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer (2008) 1.37
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol (2010) 1.33
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res (2010) 1.30
Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol (2011) 1.14
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer (2009) 1.04
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine (2015) 1.04
TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One (2012) 1.03
Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. Transl Oncol (2010) 0.99
ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology (2010) 0.97
ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Cancer Res (2013) 0.94
Cancer stem cells as 'units of selection'. Evol Appl (2012) 0.94
The oncogene ERG: a key factor in prostate cancer. Oncogene (2015) 0.93
Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer. Appl Immunohistochem Mol Morphol (2014) 0.93
Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr Rev (2008) 0.92
DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene (2014) 0.90
Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res (2013) 0.89
Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol (2015) 0.87
ETS rearrangements in prostate cancer. Asian J Androl (2012) 0.82
An improved method for constructing tissue microarrays from prostate needle biopsy specimens. J Clin Pathol (2009) 0.82
Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. Front Oncol (2014) 0.81
ETS gene fusions and prostate cancer. Am J Transl Res (2009) 0.80
ERG and CHD1 heterogeneity in prostate cancer: use of confocal microscopy in assessment of microscopic foci. Prostate (2014) 0.79
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget (2016) 0.79
Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br J Cancer (2014) 0.78
Urine markers and prostate cancer. Cent European J Urol (2011) 0.78
The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. Prostate Cancer Prostatic Dis (2010) 0.77
Microsatellites with macro-influence in ewing sarcoma. Genes (Basel) (2012) 0.76
Potential for targeted therapy in prostate cancers with ERG abnormalities. Asian J Androl (2011) 0.75
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. BMC Cancer (2017) 0.75
Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75
The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med (1993) 16.94
A Wilcoxon-type test for trend. Stat Med (1985) 13.22
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet (1993) 7.46
Scleritis-associated uveitis. Ophthalmology (1997) 7.34
Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology (1992) 6.62
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 5.26
Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer (1996) 5.24
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med (1992) 5.18
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet (2002) 5.04
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol (2000) 4.70
Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. Lancet (1986) 4.55
Mechanism of met oncogene activation. Cell (1986) 4.20
Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med (2001) 4.19
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
Nucleotide and complete amino acid sequences of Kunjin virus: definitive gene order and characteristics of the virus-specified proteins. J Gen Virol (1988) 4.09
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology (1986) 3.70
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol (2008) 3.44
Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet (1994) 3.10
Mild cervical dyskaryosis: safety of cytological surveillance. Lancet (1992) 3.09
Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. Biochemistry (1989) 3.09
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05
Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol (1996) 3.04
Tyrosine kinase receptor indistinguishable from the c-met protein. Nature (1989) 3.00
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
Adsorption and growth of Vibrio cholerae on chitin. Infect Immun (1979) 2.90
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet (2008) 2.81
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet (1993) 2.64
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol (2012) 2.45
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
Severity of scleritis and episcleritis. Ophthalmology (1994) 2.43
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol (2013) 2.41
Anterior chamber crystals following hyphema. Arch Ophthalmol (1990) 2.39
Predictors of laparoscopic complications after formal training in laparoscopic surgery. JAMA (1993) 2.37
Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep (1987) 2.37
Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg (1984) 2.36
Effect of smoking cessation on cervical lesion size. Lancet (1996) 2.35
Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous system lymphoma. Ophthalmology (1999) 2.33
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
Derivation of mouse intestinal crypts from single progenitor cells. Nature (1985) 2.31
Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer (1996) 2.30
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet (1998) 2.27
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Infectious endophthalmitis. Review of 36 cases. Ophthalmology (1982) 2.26
Chromosome mediated gene transfer of six DNA markers linked to the cystic fibrosis locus on human chromosome seven. Nucleic Acids Res (1986) 2.16
Familial cancer syndromes. Lancet (1994) 2.16
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer (2012) 2.15
Predicting survival in malignant mesothelioma. Eur Respir J (2011) 2.15
Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J (1995) 2.14
Gene mapping and positive identification of the non-structural proteins NS2A, NS2B, NS3, NS4B and NS5 of the flavivirus Kunjin and their cleavage sites. J Gen Virol (1988) 2.12
Cicatricial pemphigoid. Trans Am Ophthalmol Soc (1986) 2.10
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol (2012) 2.07
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
A region of right posterior superior temporal sulcus responds to observed intentional actions. Neuropsychologia (2004) 2.05
Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease. J Lab Clin Med (1973) 2.00
Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res (2000) 1.99